mdxhealth.com - MDXH Business Value to Revenue

MDxHealth S.A. (MDXH) - corporate logo

The EV-to-revenue ratio of MDxHealth SA (MDXH) demonstrates the influence of the molecular network in urology, where integration into hospital IT systems complicates the switching of laboratories, and the value of 796.26 reflects the most recent value of the metric. Business efficiency is based on the rapid delivery of biosamples, while patent protection and FDA approval create significant barriers to entry for new market players.

MDxHealth Inc. (MDXH): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for MDxHealth (MDXH)

- share price and consensus valuation forecast:
Fundamental company valuation:MDxHealth MDXH
Flagship merchandise of mdxhealth.com

The EV/Sales ratio measures the total enterprise value, including net debt, relative to annual sales volume. By analyzing the enterprise valuation through EV/Sales, an investor identifies the market price of one dollar of revenue regardless of the capital structure. This metric is sensitive to changes in debt load and revenue growth rates. For MDxHealth SA (MDXH), this indicator reflects the scaling potential of prostate cancer molecular diagnostics. The expansion of insurance coverage in the US directly impacts the fundamental attractiveness of this multiple.

Direct competitors

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue